Ewha Med J.  2025 Jan;48(1):e78. 10.12771/emj.2024.e78.

No difference in inflammatory mediator expression between mast cell-rich and mast cell-poor rosacea lesions in Korean patients: a comparative study

• Lee JJ
• Kwon BR
• Lee MY
• Byun JY
• Roh JY
• Choi HY
• Choi YW

• KMID: 2567567
• DOI: http://doi.org/10.12771/emj.2024.e78

Abstract

Objectives: This study aimed to evaluate the correlation between mast cell (MC) density in rosacea-affected skin and the expression of key inflammatory mediators, including IL-6, TNF-α, and cathelicidin LL-37. By comparing lesions rich in MCs with those having fewer MCs, we sought to elucidate the role of MCs in the inflammatory mechanisms underlying rosacea pathogenesis.

Methods: Specimens were collected from 20 patients diagnosed with rosacea who attended the outpatient clinic between 2008 and 2013. Each specimen underwent staining using hematoxylin/eosin, Giemsa, IL-6, LL-37, and TNF-α for both histopathological and immunohistochemical analyses. The number of stained cells was counted across 10 randomly selected dermal layers at a magnification of ×400 using light microscopy. The results were categorized based on the number of MCs counted: more than 10 MCs were classified as MC-rich, and 10 or fewer MCs as MC-poor.

Results: Among the 20 patients (10 MC-rich and 10 MC-poor), the MC-rich group demonstrated significantly higher MC counts than the MC-poor group (P<0.001). However, there were no significant differences in the expression levels of IL-6, LL-37, or TNF-α between the two groups. Additionally, MC density did not show any significant associations with patient demographics, clinical characteristics, or systemic comorbidities.

Conclusion: Increased MC density was not associated with differences in IL-6, TNF-α, or LL-37 expression in rosacea lesions. These findings suggest that MC infiltration may not directly influence the inflammatory mediator profile in rosacea. Further research is required to identify distinctive pathological features or markers that can elucidate the mechanisms of rosacea.

Keyword

Cathelicidins; Interleukin-6; Mast cells; Tumor necrosis factor-alpha; Rosacea

Figure

• 

  Fig. 1. Histopathological and immunohistochemical analysis in mast cell-rich group. (A) Histopathology of the lesional skin in MC-rich group patient. Numbers show the counting methods in MC numbers (Giemsa, ×40). (B–D) Immunohistochemical analysis (×40). (B) IL-6 staining, (C) LL-37 staining, (D) TNF-α staining.

• 

  Fig. 2. Histopathological and immunohistochemical analysis in mast cell-poor group. (A) Histopathology of the lesional skin in the MC-poor group patient (Giemsa, ×40). (B–D) Immunohistochemical analysis (×40). (B) IL-6 staining, (C) LL-37 staining, (D) TNF-α staining.

Reference

References

1. Aroni K, Tsagroni E, Kavantzas N, Patsouris E, Ioannidis E. A study of the pathogenesis of rosacea: how angiogenesis and mast cells may participate in a complex multifactorial process. Arch Dermatol Res. 2008; 300:125–131. DOI: 10.1007/s00403-007-0816-z. PMID: 18071725.

2. Muto Y, Wang Z, Vanderberghe M, Two A, Gallo RL, Di Nardo A. Mast cells are key mediators of cathelicidin-initiated skin inflammation in rosacea. J Invest Dermatol. 2014; 134(11):2728–2736. DOI: 10.1038/jid.2014.222. PMID: 24844861. PMCID: PMC4199909.

3. Aksoy B, Ekiz Ö, Unal E, Ozaydin Yavuz G, Gonul M, Kulcu Cakmak S, et al. Systemic comorbidities associated with rosacea: a multicentric retrospective observational study. Int J Dermatol. 2019; 58(6):722–728. DOI: 10.1111/ijd.14353. PMID: 30575019.

4. Mascarenhas NL, Wang Z, Chang YL, Di Nardo A. TRPV4 mediates mast cell activation in cathelicidin-induced rosacea inflammation. J Invest Dermatol. 2017; 137(4):972–975. DOI: 10.1016/j.jid.2016.10.046. PMID: 27908695.

5. Yamasaki K, Di Nardo A, Bardan A, Murakami M, Ohtake T, Coda A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med. 2007; 13:975–980. DOI: 10.1038/nm1616. PMID: 17676051.

6. Marchitto MC, Chien AL. Mast cell stabilizers in the treatment of rosacea: a review of existing and emerging therapies. Dermatol Ther. 2021; 11:1541–1549. DOI: 10.1007/s13555-021-00597-7. PMID: 34476755. PMCID: PMC8484408.

7. Wang L, Wang YJ, Hao D, Wen X, Du D, He G, et al. The theranostics role of mast cells in the pathophysiology of rosacea. Front Med. 2019; 6:324. DOI: 10.3389/fmed.2019.00324. PMID: 32047752. PMCID: PMC6997331.

8. Nakamura Y, Franchi L, Kambe N, Meng G, Strober W, Nunez G. Critical role for mast cells in interleukin-1β-driven skin inflammation associated with an activating mutation in the Nlrp3 protein. Immunity. 2012; 37(1):85–95. DOI: 10.1016/j.immuni.2012.04.013. PMID: 22819042. PMCID: PMC3411177.

9. Subramanian H, Gupta K, Ali H. Roles of Mas-related G protein-coupled receptor X2 on mast cell-mediated host defense, pseudoallergic drug reactions, and chronic inflammatory diseases. J Allergy Clin Immunol. 2016; 138(3):700–710. DOI: 10.1016/j.jaci.2016.04.051. PMID: 27448446. PMCID: PMC5014572.

10. Rosa AC, Fantozzi R. The role of histamine in neurogenic inflammation. Br J Pharmacol. 2013; 170(1):38–45. DOI: 10.1111/bph.12266. PMID: 23734637. PMCID: PMC3764847.

11. Gupta K, Subramanian H, Ali H. Modulation of host defense peptide-mediated human mast cell activation by LPS. Innate Immun. 2016; 22(1):21–30. DOI: 10.1177/1753425915610643. PMID: 26511058. PMCID: PMC4858174.

12. Mukai K, Tsai M, Saito H, Galli SJ. Mast cells as sources of cytokines, chemokines, and growth factors. Immunol Rev. 2018; 282(1):121–150. DOI: 10.1111/imr.12634. PMID: 29431212. PMCID: PMC5813811.

13. Holmes AD, Spoendlin J, Chien AL, Baldwin H, Chang ALS. Evidence-based update on rosacea comorbidities and their common physiologic pathways. J Am Acad Dermatol. 2018; 78(1):156–166. DOI: 10.1016/j.jaad.2017.07.055. PMID: 29089181.